Fernando Tricta

2.7k total citations
49 papers, 1.7k citations indexed

About

Fernando Tricta is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Fernando Tricta has authored 49 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 38 papers in Hematology and 13 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Fernando Tricta's work include Hemoglobinopathies and Related Disorders (40 papers), Iron Metabolism and Disorders (26 papers) and Blood groups and transfusion (16 papers). Fernando Tricta is often cited by papers focused on Hemoglobinopathies and Related Disorders (40 papers), Iron Metabolism and Disorders (26 papers) and Blood groups and transfusion (16 papers). Fernando Tricta collaborates with scholars based in United States, Egypt and Canada. Fernando Tricta's co-authors include Antonio Piga, Renzo Galanello, Vincenzo De Sanctis, Amal El‐Beshlawy, Alan R. Cohen, Michael Spino, Mohamed Badr, Youssef Al‐Tonbary, Ahmed Mansour and John Connelly and has published in prestigious journals such as Blood, PLoS ONE and Annals of Neurology.

In The Last Decade

Fernando Tricta

46 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fernando Tricta United States 16 917 876 305 301 208 49 1.7k
Debbie Trinder Australia 29 721 0.8× 1.4k 1.7× 356 1.2× 55 0.2× 833 4.0× 66 2.5k
Martine Ropert France 22 960 1.0× 1.3k 1.5× 231 0.8× 83 0.3× 820 3.9× 93 2.0k
Judith Simcox United States 21 320 0.3× 555 0.6× 733 2.4× 59 0.2× 236 1.1× 39 2.3k
Viktor Kožich Czechia 36 59 0.1× 205 0.2× 1.4k 4.5× 415 1.4× 109 0.5× 137 3.7k
Yong Du United States 29 176 0.2× 77 0.1× 697 2.3× 23 0.1× 55 0.3× 96 2.0k
Xin Wei China 22 52 0.1× 90 0.1× 574 1.9× 71 0.2× 132 0.6× 92 1.8k
Akira Nishio Japan 21 67 0.1× 57 0.1× 315 1.0× 51 0.2× 256 1.2× 129 1.3k
Cathal McCarthy Ireland 20 161 0.2× 37 0.0× 402 1.3× 446 1.5× 103 0.5× 51 1.5k
Hyo Jung Kim South Korea 20 50 0.1× 242 0.3× 331 1.1× 27 0.1× 45 0.2× 110 1.4k
Yan Jiao United States 20 45 0.0× 79 0.1× 893 2.9× 61 0.2× 235 1.1× 71 1.8k

Countries citing papers authored by Fernando Tricta

Since Specialization
Citations

This map shows the geographic impact of Fernando Tricta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Tricta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Tricta more than expected).

Fields of papers citing papers by Fernando Tricta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Tricta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Tricta. The network helps show where Fernando Tricta may publish in the future.

Co-authorship network of co-authors of Fernando Tricta

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Tricta. A scholar is included among the top collaborators of Fernando Tricta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Tricta. Fernando Tricta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Badawy, Sherif M., et al.. (2024). Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data. Blood Advances. 8(21). 5641–5649. 3 indexed citations
3.
Kwiatkowski, Janet L., Sujit Sheth, Antonis Kattamis, et al.. (2024). Efficacy and Safety of Combination Therapy with Oral Iron Chelators Deferiprone and Deferasirox in Patients with β-Thalassemia Major: A Systematic Literature Review. Blood. 144(Supplement 1). 5268–5268.
4.
Hamdy, Mona, Amal El‐Beshlawy, Julie Kanter, et al.. (2023). Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study. Pediatric Blood & Cancer. 71(1). e30711–e30711. 4 indexed citations
5.
6.
7.
Elalfy, Mohsen Saleh, Mona Hamdy, Amal El‐Beshlawy, et al.. (2022). Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Advances. 7(4). 611–619. 16 indexed citations
8.
Soulières, Denis, et al.. (2022). The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease. Annals of Hematology. 101(3). 533–539. 6 indexed citations
9.
Kwiatkowski, Janet L., Mona Hamdy, Amal El‐Beshlawy, et al.. (2021). Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Advances. 6(4). 1243–1254. 33 indexed citations
10.
Kerbauy, Lucila Nassif, Laércio Alberto Rosemberg, Sandra Regina Loggetto, et al.. (2021). Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study. Hematology Transfusion and Cell Therapy. 45(1). 7–15. 4 indexed citations
11.
Wahidiyat, Pustika Amalia, et al.. (2020). An insight into Indonesian current thalassaemia care and challenges. ISBT Science Series. 15(3). 334–341. 10 indexed citations
12.
Tricta, Fernando, Mariagrazia Felisi, Amal El‐Beshlawy, et al.. (2019). Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients. Blood. 134(Supplement_1). 3552–3552. 2 indexed citations
13.
Kwiatkowski, Janet L., et al.. (2017). Safety of Deferiprone in Individuals with Sickle Cell Disease. Blood. 130. 2249–2249. 2 indexed citations
14.
15.
Lee, Todd A., et al.. (2014). Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature. Expert Review of Pharmacoeconomics & Outcomes Research. 14(5). 651–660. 4 indexed citations
16.
Au, Wing‐Yan, Xin Sun, Hong‐Ying Gao, et al.. (2014). Assessment of Iron Overload in Very Young Children with Limited Thalassemia Care Resources in South China. Hemoglobin. 38(2). 119–126. 7 indexed citations
17.
Hanauske‐Abel, Hartmut M., Deepti Saxena, Paul Palumbo, et al.. (2013). Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection. PLoS ONE. 8(9). e74414–e74414. 33 indexed citations
18.
Ceci, Adriana, Paola Baiardi, Mariagrazia Felisi, et al.. (2002). The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients. British Journal of Haematology. 118(1). 330–336. 174 indexed citations
19.
Kim, Sung Soo, Fernando Tricta, & David G. Mohler. (2001). Multifocal Pseudoaneurysmal Bone Cysts in Sickle Cell Disease. Orthopedics. 24(5). 489–491. 1 indexed citations
20.
Cohen, Alan R., et al.. (1998). A Multi‐Center Safety Trial of the Oral Iron Chelator Deferiprone. Annals of the New York Academy of Sciences. 850(1). 223–226. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debbie Trinder Breakdown of academic impact, for papers by Martine Ropert Breakdown of academic impact, for papers by Judith Simcox Breakdown of academic impact, for papers by Viktor Kožich Breakdown of academic impact, for papers by Yong Du Breakdown of academic impact, for papers by Xin Wei Breakdown of academic impact, for papers by Akira Nishio Breakdown of academic impact, for papers by Cathal McCarthy Breakdown of academic impact, for papers by Hyo Jung Kim Breakdown of academic impact, for papers by Yan Jiao
Rankless by CCL
2026